A 'flyover' biotech launches in Texas with four Ron DePinho-founded companies under its belt
In his 13 years at Genzyme, Michael Wyzga noticed something about East Coast drugmakers. Execs would often jet from Boston or New York to San Francisco to find more assets, and completely miss the work being done in flyover states, like Texas or Wisconsin.
“If it doesn’t come out of MGH or MIT or Harvard, probably not that interesting,” he said of the mindset.
Now, he and some well-known industry players are looking to change that, and they’ve reeled in just over $38 million to do it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,000+ biopharma pros reading Endpoints daily — and it's free.